View : 595 Download: 0

Prognostic Value of Ga-68-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery A Comparison Study With Dynamic Contrast Enhanced MRI

Title
Prognostic Value of Ga-68-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery A Comparison Study With Dynamic Contrast Enhanced MRI
Authors
Kim, Yong-ilYoon, Hai-JeonPaeng, Jin ChulCheon, Gi JeongLee, Dong SooChung, June-KeyKim, E. EdmundMoon, Woo KyungKang, Keon Wook
Ewha Authors
윤혜전
SCOPUS Author ID
윤혜전scopus
Issue Date
2016
Journal Title
CLINICAL NUCLEAR MEDICINE
ISSN
0363-9762JCR Link

1536-0229JCR Link
Citation
CLINICAL NUCLEAR MEDICINE vol. 41, no. 8, pp. 614 - 620
Keywords
Ga-68angiogenesisbreast cancerintegrinRGD
Publisher
LIPPINCOTT WILLIAMS &

WILKINS
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Purpose: We performed pretreatment angiogenesis imaging (Ga-68-NOTA-arginyl-glycyl-aspartic acid [RGD] PET/CT) to compare its prognostic value to dynamic contrast-enhanced (DCE) MRI in breast cancer patients. Methods: Forty-four female patients with stage II or III breast cancer (aged 47.3 +/- 8.1 years) were prospectively enrolled and underwent Ga-68-NOTA-RGD PET/CT and DCE-MRI imaging. All patients received neoadjuvant chemotherapy and underwent surgery. With pretreatment Ga-68-NOTA-RGD PET/CT, SUVmax of the tumor in the torso (-T) and regional (-R) images were measured. With pretreatment DCE-MRI, the largest diameter of the tumor and maximum enhancement index (EImax; EImax = [highest signal / baseline signal] - 1) of the tumor were assessed. Results: Ten patients (22.7%) were found to have breast cancer recurrence after 17.9 +/- 11.2 months. The SUVmax-R (P = 0.017, cutoff >2.79) of Ga-68-NOTA-RGD PET/CT, the largest diameter of tumor (P = 0.017, cutoff >6.3 cm), and the EImax (P = 0.008, cutoff >5.38) of DCE-MRI showed significant results by univariate analysis. The 3-year disease-free survival of SUVmax-R was 91.7% versus 59.1% by Kaplan-Meier analysis (hazard ratio, 5.379). Multivariable analysis demonstrated that SUVmax-R with tumor diameter or EImax were the significant parameters. In addition, the combined parameters of SUVmax-R and EImax revealed better predictive value for prediction of breast cancer recurrence (75.0%) than each parameter of SUVmax-R (64.2%) and EImax (68.7%). Conclusions: Increased angiogenic activity of regional Ga-68-NOTA-RGD PET/CT (SUVmax-R) can be an early prognostic marker for the prediction of breast cancer recurrence.
DOI
10.1097/RLU.0000000000001274
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE